Drug interactions
Paclitaxel + Sorafenib
Severity: Moderate
Paclitaxel and Sorafenib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Sorafenib has been reported to inhibit CYP2C8 in vitro, and paclitaxel is cleared mainly by CYP2C8 with a contribution from CYP3A4. Exposure to paclitaxel may rise, which could worsen neutropenia and neuropathy. In clinical combination studies the effect on paclitaxel exposure was modest and variable.
What this interaction means in plain words
Paclitaxel and Sorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Paclitaxel belongs to Oncology; Sorafenib belongs to Oncology.
Why it happens
Sorafenib may inhibit CYP2C8-mediated metabolism of paclitaxel, reducing its clearance.
What to do
Monitor blood counts and signs of peripheral neuropathy when the two are combined. Reduce the paclitaxel dose if severe toxicity occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Paclitaxel and Sorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Paclitaxel
Other interactions of Sorafenib
Frequently asked questions
Can I take Paclitaxel with Sorafenib?
MediHelp rates the interaction as moderate. Paclitaxel and Sorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Sorafenib has been reported to inhibit CYP2C8 in vitro, and paclitaxel is cleared mainly by CYP2C8 with a contribution from CYP3A4. Exposure to paclitaxel may rise, which could worsen neutropenia and neuropathy. In clinical combination studies the effect on paclitaxel exposure was modest and variable.
How serious is the interaction between Paclitaxel and Sorafenib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and signs of peripheral neuropathy when the two are combined. Reduce the paclitaxel dose if severe toxicity occurs.
What other medicines interact with Paclitaxel?
MediHelp also lists interactions of Paclitaxel with, for example, Adenovirus types 4 and 7 live, Cobicistat, Cyclosporine. The full list is on the Paclitaxel page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
